drugset
drugset / Trial / NCT03371173

ORal IrON Supplementation With Ferric Maltol in Patients With Pulmonary Hypertension (ORION-PH-1)

NCT03371173 ↗

Phase 3 Terminated 22 enrolled Hannover Medical School Shields, Shields and Associates · collab
NaSingle-groupOpen-labelTreatment

Summary

This is an explorative, open-label, uncontrolled, single center study to explore the preliminary safety, tolerability and efficacy of oral ferric maltol in treating iron deficiency in patients with pulmonary hypertension and iron deficiency anemia.

Timeline

Start
2018-03-27
Primary completion
2020-03-19
Completion
2020-03-19

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric maltol Small molecule 30 mg Oral

Indications

iron deficiency anemia pulmonary hypertension